article thumbnail

Vascular inflammation in chronic kidney disease: the role of uremic toxins in macrophage activation

Frontiers in Cardiovascular Medicine

Chronic kidney disease (CKD) is a progressive condition characterized by the gradual loss of kidney function, leading to the accumulation of uremic toxins in the bloodstream. This review article explores the intricate mechanisms by which uremic toxins accelerate vascular inflammation.

article thumbnail

SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease

Med Page Today

(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular risk factors, a prespecified.

article thumbnail

Patients With Tuberculosis at Increased Risk of Gout

HCPLive

Other risk factors in the population included PZA or ETB use, hypertension, heart failure, and chronic kidney disease.

article thumbnail

Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes

Medical Xpress - Cardiology

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

article thumbnail

2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Circulation

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

article thumbnail

Urinary Prostaglandin E2 Excretion and the Risk of Cardiovascular and Kidney Disease

Journal of the American Heart Association

BackgroundInhibition of prostaglandin synthesis by nonsteroidal anti‐inflammatory drugs is associated with cardiovascular mortality and kidney disease. Longitudinal associations with cardiovascular mortality and kidney outcomes (eGFR <60 or <45 mL/min per 1.73

article thumbnail

America’s CKM Syndrome Problem

CardiacWire

Officially published by the AHA six months ago, CKM syndrome defines the connections and risks associated with obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. White) to assess their CKM stages, finding the following breakdown: Stage 0 (no risk factors) – 10.6%